Corcept Therapeutics (CORT) Stock Forecast, Price Target & Predictions
CORT Stock Forecast
Corcept Therapeutics stock forecast is as follows: an average price target of $68.00 (represents a 25.21% upside from CORT’s last price of $54.31) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
CORT Price Target
The average price target for Corcept Therapeutics (CORT) is $68.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $80.00 to $38.00. This represents a potential 25.21% upside from CORT's last price of $54.31.
CORT Analyst Ratings
According to 6 Wall Street analysts, Corcept Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CORT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Corcept Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 18, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $80.00 | $47.17 | 69.60% | 47.30% |
| Sep 30, 2024 | Joon Lee | Truist Financial | $76.00 | $43.93 | 73.00% | 39.94% |
| Aug 15, 2024 | Edward Nash | Canaccord Genuity | $78.00 | $34.71 | 124.72% | 43.62% |
| Jul 30, 2024 | David Amsellem | Piper Sandler | $38.00 | $36.12 | 5.20% | -30.03% |
| Jul 30, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $45.00 | $36.53 | 23.19% | -17.14% |
| Jun 12, 2024 | Edward Nash | Canaccord Genuity | $38.00 | $32.79 | 15.89% | -30.03% |
| Jun 10, 2024 | David Amsellem | Piper Sandler | $35.00 | $31.51 | 11.08% | -35.56% |
| Jun 04, 2024 | Joon Lee | Truist Financial | $65.00 | $31.59 | 105.76% | 19.68% |
| May 02, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $40.00 | $23.88 | 67.50% | -26.35% |
| Dec 09, 2022 | - | H.C. Wainwright | $30.00 | $23.01 | 30.38% | -44.76% |
The latest Corcept Therapeutics stock forecast, released on Oct 18, 2024 by Swayampakula Ramakanth from H.C. Wainwright, set a price target of $80.00, which represents a 69.60% increase from the stock price at the time of the forecast ($47.17), and a 47.30% increase from CORT last price ($54.31).
Corcept Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 9 |
| Avg Price Target | - | $78.00 | $55.00 |
| Last Closing Price | $54.31 | $54.31 | $54.31 |
| Upside/Downside | -100.00% | 43.62% | 1.27% |
In the current month, the average price target of Corcept Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Corcept Therapeutics's last price of $54.31. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 18, 2024 | Sandler O'Neill | Buy | Buy | Hold |
| Oct 18, 2024 | Sandler O'Neil | Underperform | Underperform | Hold |
| Oct 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 25, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Sep 18, 2024 | Sandler O'Neil | Underperform | Underperform | Hold |
| Sep 18, 2024 | Sandler O'Neill | Buy | Buy | Hold |
| Sep 18, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 15, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Jul 30, 2024 | Truist Financial | Buy | Buy | Hold |
| Jul 30, 2024 | Sandler O'Neill | Underperform | Underperform | Hold |
Corcept Therapeutics's last stock rating was published by Sandler O'Neill on Oct 18, 2024. The company gave CORT a "Buy" rating, the same as its previous rate.
Corcept Therapeutics Financial Forecast
Corcept Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $135.41M | $123.60M | $117.72M | $105.65M | $103.06M | $101.73M | $103.39M | $93.69M | $98.82M | $96.13M | $91.59M | $79.44M | $85.73M | $86.33M | $88.56M | $93.25M | $87.89M | $81.50M | $72.26M | $64.83M | $57.66M | $27.60M |
| Avg Forecast | $214.23M | $205.38M | $196.57M | $189.80M | $198.04M | $171.97M | $155.14M | $141.19M | $129.27M | $119.71M | $109.60M | $104.89M | $105.08M | $107.57M | $101.00M | $98.88M | $100.57M | $97.19M | $86.84M | $91.81M | $90.36M | $90.87M | $90.13M | $87.00M | $87.67M | $78.00M | $70.88M | $69.29M | $65.90M | $20.70M |
| High Forecast | $228.70M | $219.24M | $209.85M | $200.68M | $212.08M | $172.38M | $165.61M | $141.19M | $137.99M | $120.13M | $117.00M | $111.97M | $112.18M | $107.57M | $101.00M | $98.88M | $100.57M | $97.19M | $86.84M | $91.81M | $90.36M | $90.87M | $90.13M | $87.00M | $87.67M | $78.00M | $70.88M | $69.29M | $79.08M | $24.84M |
| Low Forecast | $199.50M | $191.25M | $183.05M | $176.64M | $183.87M | $171.55M | $144.46M | $141.19M | $120.38M | $118.93M | $102.06M | $97.67M | $97.85M | $107.57M | $101.00M | $98.88M | $100.57M | $97.19M | $86.84M | $91.81M | $90.36M | $90.87M | $90.13M | $87.00M | $87.67M | $78.00M | $70.88M | $69.29M | $52.72M | $16.56M |
| # Analysts | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 1 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | 1.05% | 1.03% | 1.07% | 1.01% | 0.98% | 0.95% | 1.02% | 0.95% | 0.98% | 0.99% | 1.05% | 0.87% | 0.95% | 0.95% | 0.98% | 1.07% | 1.00% | 1.04% | 1.02% | 0.94% | 0.88% | 1.33% |
Corcept Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $141.19M, with a low forecast of $141.19M, and a high forecast of $141.19M. CORT's average Quarter revenue forecast represents a 4.27% increase compared to the company's last Quarter revenue of $135.41M (Dec 23).
Corcept Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 1 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | $32.30M | $31.18M | $29.58M | $14.85M | $22.50M | $32.69M | $31.43M | $27.57M | $37.60M | $37.15M | $32.92M | $20.93M | $31.67M | $26.53M | $37.79M | $41.26M | $38.47M | $36.27M | $27.52M | $21.66M | $21.63M | $4.75M |
| Avg Forecast | $67.90M | $65.10M | $62.31M | $60.16M | $62.77M | $54.51M | $49.17M | $39.15M | $40.97M | $37.94M | $34.74M | $35.59M | $33.84M | $33.87M | $31.80M | $32.35M | $31.66M | $30.60M | $27.34M | $23.61M | $28.45M | $28.61M | $28.38M | $34.36M | $27.60M | $24.56M | $22.31M | $24.89M | $24.00M | $3.17M |
| High Forecast | $72.49M | $69.49M | $66.51M | $63.61M | $67.22M | $54.64M | $52.49M | $46.98M | $43.74M | $38.08M | $37.09M | $42.71M | $40.61M | $33.87M | $31.80M | $38.82M | $31.66M | $30.60M | $27.34M | $28.33M | $28.45M | $28.61M | $28.38M | $41.23M | $27.60M | $24.56M | $22.31M | $29.87M | $28.80M | $3.80M |
| Low Forecast | $63.23M | $60.62M | $58.02M | $55.99M | $58.28M | $54.38M | $45.79M | $31.32M | $38.15M | $37.70M | $32.35M | $28.47M | $27.08M | $33.87M | $31.80M | $25.88M | $31.66M | $30.60M | $27.34M | $18.89M | $28.45M | $28.61M | $28.38M | $27.49M | $27.60M | $24.56M | $22.31M | $19.91M | $19.20M | $2.53M |
| Surprise % | - | - | - | - | - | - | - | - | 0.79% | 0.82% | 0.85% | 0.42% | 0.66% | 0.97% | 0.99% | 0.85% | 1.19% | 1.21% | 1.20% | 0.89% | 1.11% | 0.93% | 1.33% | 1.20% | 1.39% | 1.48% | 1.23% | 0.87% | 0.90% | 1.50% |
1 analysts predict CORT's average Quarter EBITDA for Mar 24 to be $39.15M, with a high of $46.98M and a low of $31.32M. This is 21.20% upper than Corcept Therapeutics's previous annual EBITDA (Dec 23) of $32.30M.
Corcept Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 1 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 8 |
| Net Income | - | - | - | - | - | - | - | - | $31.36M | $31.17M | $27.36M | $15.88M | $16.60M | $34.61M | $27.41M | $22.80M | $32.05M | $30.47M | $26.52M | $23.46M | $25.99M | $21.63M | $28.33M | $30.07M | $29.38M | $26.34M | $20.19M | $18.27M | $17.46M | $4.39M |
| Avg Forecast | $59.70M | $52.31M | $46.91M | $43.50M | $42.76M | $32.06M | $26.16M | $32.18M | $29.35M | $24.83M | $17.06M | $29.26M | $28.85M | $26.03M | $26.33M | $26.60M | $25.03M | $23.92M | $18.36M | $26.82M | $18.36M | $23.36M | $24.75M | $25.97M | $29.11M | $22.06M | $20.30M | $22.12M | $19.64M | $2.93M |
| High Forecast | $64.94M | $56.90M | $51.03M | $57.57M | $50.85M | $32.51M | $28.45M | $38.62M | $31.70M | $29.34M | $18.56M | $35.11M | $34.62M | $26.03M | $26.33M | $31.92M | $25.03M | $23.92M | $18.36M | $32.18M | $18.36M | $23.36M | $24.75M | $31.16M | $29.11M | $22.06M | $20.30M | $26.55M | $23.57M | $3.51M |
| Low Forecast | $54.37M | $47.63M | $42.72M | $31.98M | $30.05M | $31.61M | $23.82M | $25.75M | $24.66M | $18.06M | $15.53M | $23.40M | $23.08M | $26.03M | $26.33M | $21.28M | $25.03M | $23.92M | $18.36M | $21.45M | $18.36M | $23.36M | $24.75M | $20.77M | $29.11M | $22.06M | $20.30M | $17.70M | $15.71M | $2.34M |
| Surprise % | - | - | - | - | - | - | - | - | 1.07% | 1.26% | 1.60% | 0.54% | 0.58% | 1.33% | 1.04% | 0.86% | 1.28% | 1.27% | 1.44% | 0.88% | 1.42% | 0.93% | 1.14% | 1.16% | 1.01% | 1.19% | 0.99% | 0.83% | 0.89% | 1.50% |
Corcept Therapeutics's average Quarter net income forecast for Mar 24 is $32.18M, with a range of $25.75M to $38.62M. CORT's average Quarter net income forecast represents a 2.64% increase compared to the company's last Quarter net income of $31.36M (Dec 23).
Corcept Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 1 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 8 |
| SG&A | - | - | - | - | - | - | - | - | $47.15M | $45.26M | $43.28M | $48.56M | $42.32M | $35.16M | $37.81M | $37.55M | $32.28M | $30.53M | $30.03M | $29.51M | $25.70M | $26.52M | $25.57M | $27.54M | $27.13M | $24.25M | $24.59M | $24.39M | $18.44M | $15.04M |
| Avg Forecast | $73.77M | $70.72M | $67.69M | $65.36M | $68.19M | $59.22M | $53.42M | $53.01M | $44.51M | $41.22M | $37.74M | $48.19M | $29.06M | $37.04M | $34.78M | $43.81M | $34.63M | $33.47M | $29.90M | $33.72M | $31.12M | $31.29M | $31.04M | $23.78M | $30.19M | $26.86M | $24.41M | $29.52M | $20.75M | $10.02M |
| High Forecast | $78.75M | $75.50M | $72.26M | $69.10M | $73.03M | $59.36M | $57.03M | $63.61M | $47.52M | $41.37M | $40.29M | $57.83M | $34.87M | $37.04M | $34.78M | $52.57M | $34.63M | $33.47M | $29.90M | $40.47M | $31.12M | $31.29M | $31.04M | $28.54M | $30.19M | $26.86M | $24.41M | $35.43M | $24.89M | $12.03M |
| Low Forecast | $68.70M | $65.86M | $63.03M | $60.83M | $63.32M | $59.07M | $49.75M | $42.41M | $41.45M | $40.95M | $35.15M | $38.55M | $23.25M | $37.04M | $34.78M | $35.05M | $34.63M | $33.47M | $29.90M | $26.98M | $31.12M | $31.29M | $31.04M | $19.02M | $30.19M | $26.86M | $24.41M | $23.62M | $16.60M | $8.02M |
| Surprise % | - | - | - | - | - | - | - | - | 1.06% | 1.10% | 1.15% | 1.01% | 1.46% | 0.95% | 1.09% | 0.86% | 0.93% | 0.91% | 1.00% | 0.88% | 0.83% | 0.85% | 0.82% | 1.16% | 0.90% | 0.90% | 1.01% | 0.83% | 0.89% | 1.50% |
Corcept Therapeutics's average Quarter SG&A projection for Mar 24 is $53.01M, based on 1 Wall Street analysts, with a range of $42.41M to $63.61M. The forecast indicates a 12.42% rise compared to CORT last annual SG&A of $47.15M (Dec 23).
Corcept Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 1 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 8 |
| EPS | - | - | - | - | - | - | - | - | $0.29 | $0.31 | $0.27 | $0.15 | $0.15 | $0.32 | $0.26 | $0.22 | $0.28 | $0.26 | $0.23 | $0.20 | $0.22 | $0.19 | $0.25 | $0.26 | $0.26 | $0.23 | $0.18 | $0.16 | $0.15 | $0.04 |
| Avg Forecast | $0.53 | $0.46 | $0.41 | $0.38 | $0.38 | $0.28 | $0.23 | $0.22 | $0.26 | $0.22 | $0.15 | $0.20 | $0.24 | $0.23 | $0.24 | $0.23 | $0.23 | $0.21 | $0.17 | $0.22 | $0.17 | $0.21 | $0.22 | $0.22 | $0.26 | $0.20 | $0.18 | $0.19 | $0.18 | $0.02 |
| High Forecast | $0.57 | $0.50 | $0.45 | $0.51 | $0.45 | $0.29 | $0.25 | $0.24 | $0.28 | $0.26 | $0.16 | $0.22 | $0.26 | $0.23 | $0.24 | $0.23 | $0.23 | $0.21 | $0.17 | $0.22 | $0.17 | $0.21 | $0.22 | $0.22 | $0.26 | $0.20 | $0.18 | $0.19 | $0.22 | $0.02 |
| Low Forecast | $0.48 | $0.42 | $0.38 | $0.28 | $0.26 | $0.28 | $0.21 | $0.20 | $0.22 | $0.16 | $0.14 | $0.18 | $0.22 | $0.23 | $0.24 | $0.23 | $0.23 | $0.21 | $0.17 | $0.22 | $0.17 | $0.21 | $0.22 | $0.22 | $0.26 | $0.20 | $0.18 | $0.19 | $0.14 | $0.02 |
| Surprise % | - | - | - | - | - | - | - | - | 1.12% | 1.42% | 1.80% | 0.76% | 0.63% | 1.37% | 1.10% | 0.95% | 1.24% | 1.21% | 1.39% | 0.92% | 1.33% | 0.90% | 1.12% | 1.17% | 0.99% | 1.16% | 0.99% | 0.84% | 0.83% | 2.00% |
According to 1 Wall Street analysts, Corcept Therapeutics's projected average Quarter EPS for Mar 24 is $0.22, with a low estimate of $0.20 and a high estimate of $0.24. This represents a -24.14% decrease compared to CORT previous annual EPS of $0.29 (Dec 23).
Corcept Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SNSE | Sensei Biotherapeutics | $0.48 | $5.50 | 1045.83% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| NUVB | Nuvation Bio | $2.59 | $6.75 | 160.62% | Buy |
| ANAB | AnaptysBio | $19.97 | $52.00 | 160.39% | Buy |
| RARE | Ultragenyx Pharmaceutical | $45.13 | $106.93 | 136.94% | Buy |
| MLYS | Mineralys Therapeutics | $12.86 | $30.00 | 133.28% | Buy |
| ERAS | Erasca | $2.79 | $6.50 | 132.97% | Buy |
| NXTC | NextCure | $1.31 | $3.00 | 129.01% | Buy |
| KROS | Keros Therapeutics | $53.62 | $102.60 | 91.35% | Buy |
| IDYA | IDEAYA Biosciences | $25.86 | $46.58 | 80.12% | Buy |
| CYTK | Cytokinetics | $51.09 | $83.23 | 62.91% | Buy |
| MGTX | MeiraGTx | $5.98 | $9.00 | 50.50% | Buy |
| DYN | Dyne Therapeutics | $29.68 | $43.88 | 47.84% | Buy |
| EWTX | Edgewise Therapeutics | $31.51 | $45.00 | 42.81% | Buy |
| HALO | Halozyme Therapeutics | $44.81 | $57.00 | 27.20% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
| CORT | Corcept Therapeutics | $54.31 | $68.00 | 25.21% | Buy |
| INSM | Insmed | $73.72 | $76.25 | 3.43% | Buy |
| AGIO | Agios Pharmaceuticals | $54.41 | $48.00 | -11.78% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |